Beyond Seizures: Addressing Neurodevelopment, Quality of Life and Emerging Therapies in Dravet Syndrome Patients

To participate in this activity, please:

Log in Sign Up

The combined developmental and epileptic encephalopathy of Dravet syndrome provides significant diagnostic and treatment challenges. This activity focuses on key characteristics and clinical presentations of Dravet syndrome with the aim of early identification of persons with the syndrome, timely initiation and appropriate use of approved medications, and the need for a multidisciplinary care plan, particularly as individuals transition into adulthood. Dr. Wirrell also provides an overview of investigational disease-modifying therapies.

This content is also available as a podcast here.

 

Course Credit:

0.75 AAPA Category I CME Credit
0.75 ACPE Contact Hours
0.75 AMA PRA Category 1 CreditsTM
0.75 ANCC Contact Hours
0.75 CA-BRN Contact Hours
0.50 Pharmacology Hours

Dates:

Opens: 2026-04-28
Closes: 2027-04-28

Target Audience:

This activity was developed for pediatricians, primary care physicians, neurologists and epileptologists, nurse practitioners, nurses, physician associates, pharmacists.

This activity is supported by an educational grant from UCB.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 0.75 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

The Annenberg Center has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 hours AAPA Category 1 CME credits. Approval is valid until April 28, 2027. Physician Associates should only claim credit commensurate with the extent of their participation.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 ANCC contact hours, including 0.5 pharmacology hours.

Provider is approved by the California Board of Registered Nursing, Provider #13664, for 0.75 contact hours.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

Additional Content Planners

Mitra Habibi, PharmD (Medical Writer)
No significant relationships to disclose.

Amber Lambert, MSN, FNP-C, DNP (Nurse Reviewer)
No significant relationships to disclose.

Amanda Prather, PA-C (Peer Reviewer)
No significant relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Elaine Wirrell, MD headshot

    Elaine Wirrell, MD

    Chair, Child and Adolescent Neurology
    Mayo Clinic
    Member, Medical Advisory Board
    Dravet Syndrome Foundation
    Rochester, Minnesota

Learning Objectives

  • Summarize key characteristics of Dravet syndrome, its clinical presentation to include signs and symptoms beyond seizures, natural history, burden of disease, and unmet needs.
  • Develop an individualized, comprehensive treatment plan for children and adults with Dravet syndrome, using standard-of-care management strategies to alleviate the disease and treatment burden for patients and caregivers.
  • Outline data surrounding investigational therapies for Dravet syndrome, including their ability to bridge unmet needs for patients with the disease.

Faculty Disclosures

Elaine Wirrell, MD

Consultant: Biocodex, Jazz Pharmaceuticals

Data Safety Monitoring Board: Encoded Therapeutics, GRIN Therapeutics, Neurocrine Biosciences